Back to Search
Start Over
Ibrutinib Could Suppress CA-125 in Ovarian Cancer: A Hypothesis
- Source :
- Applied Sciences, Vol 11, Iss 1, p 222 (2020)
- Publication Year :
- 2020
- Publisher :
- MDPI AG, 2020.
-
Abstract
- Ibrutinib is a small-molecule inhibitor of Bruton’s tyrosine kinase, an enzyme central in B cell development. It is indicated as a therapy for certain hematological diseases such as chronic lymphocytic leukemia (CLL), but also exerts off-target effects on several receptors and kinases. In this paper, we hypothesize that ibrutinib may suppress the tumor marker CA-125 in ovarian cancer. The hypothesis is based on an observation of CA-125 normalization in a patient with low-grade serous ovarian cancer who received ibrutinib for concurrent CLL. We propose a mechanistic model explaining this possible drug effect as a foundation for further research.
Details
- Language :
- English
- ISSN :
- 20763417
- Volume :
- 11
- Issue :
- 1
- Database :
- Directory of Open Access Journals
- Journal :
- Applied Sciences
- Publication Type :
- Academic Journal
- Accession number :
- edsdoj.35c56b8ae945a19e7926b22073a56e
- Document Type :
- article
- Full Text :
- https://doi.org/10.3390/app11010222